Blinatumomab may induce graft versus host leukemia in patients with pre‐B ALL relapsing after hematopoietic stem cell transplant

Blinatumomab, a bispecific T‐cell engager monoclonal antibody used to manage Philadelphia chromosome‐negative relapsed or refractory B‐cell precursor acute lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Waqas, Gul, Zartash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974418/
https://www.ncbi.nlm.nih.gov/pubmed/27525074
http://dx.doi.org/10.1002/ccr3.604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974418/
https://www.ncbi.nlm.nih.gov/pubmed/27525074
http://dx.doi.org/10.1002/ccr3.604

Ejemplares similares